Uncategorized
DME patients with vitreomacular adhesions may have better visual outcomes after anti-VEGF treatment
Anti-VEGF injections may improve visual outcomes in diabetic macular edema patients who have vitreomacular adhesions, according to the READ-3 study.The retrospective cohort study evaluated 26 DME patients who had a vitreomacular adhesion (VMA) and 98 DME patients who did not have a VMA. Patients were randomized to receive monthly injections of either 0.5 mg or 0.2 mg of Lucentis (ranibizumab, Genentech).